CommentCumulative burden of disease: a relevant measure of the late side-effects of cancer treatment
References (9)
- et al.
Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines
Radiother Oncol
(2006) - et al.
Proton beam therapy: the context, future direction and challenges become clearer
Clin Oncol
(2014) - et al.
Treatment of children and adolescents with Hodgkin lymphoma without radiotherapy for patients in complete remission after chemotherapy: final results of the multinational trial GPOH-HD95
J Clin Oncol
(2013) - et al.
Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study
Lancet Oncol
(2016)
Cited by (2)
The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE)
2017, The LancetCitation Excerpt :Second, the traditional methods used to characterise long-term morbidity in survivor populations, such as cumulative incidence and prevalence of health conditions,6–8,21 only describe the first occurrence of an outcome and do not adequately show the many different morbidities that occur in the survivorship population. By analysing the cumulative burden (a method of disease burden measurement that incorporates multiple health conditions and recurrent events into a single metric) in the SJLIFE cohort, we define the landscape of disease burden by providing a clinically informative description of the long-term pattern of morbidity in survivors of childhood cancer.12,22 Using cumulative prevalence, we previously reported that by age 45 years, 95·2% of survivors in the SJLIFE cohort had at least one CHC and 80% had at least one serious, disabling, or life-threatening CHC.5
HOW TO PUT CARDIO-ONCOLOGY REHABILITATION (CORE) IN DAILY CLINICAL PRACTICE. BENEFITS, INDICATIONS, BARRIERS AND POSSIBLE SOLUTIONS
2023, Journal of Cancer Rehabilitation